Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000392 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT00000392: Completed Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
NCT00000392 is a Phase 2 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 215 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000392, a Phase 2 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.
Primary Outcome
Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)
Interventions
- DRUG Placebo
- DRUG Peptide T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 1990-01 |
| Est. Completion | 1996-08 |
| Phase | Phase 2 |
What the finished NCT00000392 record still lists
NCT00000392 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00000392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000392 about?
NCT00000392 is a clinical study titled "Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.". To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive...
What is the current status of trial NCT00000392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 1990-01. Estimated completion is 1996-08.
What interventions are being tested in trial NCT00000392?
The interventions under investigation include: Placebo (DRUG), Peptide T (DRUG).
Who is sponsoring clinical trial NCT00000392?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000392's enrollment target sits among peer trials
215 289th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia